Drug intelligence / Profile preview

AB-Implalac

Development stage: Preclinical
Lead developer: AB-BIOTICS
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

AB-Implalac is a probiotic formula developed by AB-BIOTICS specifically designed to support oral health and manage peri-implantitis. It functions by restoring the balance of the oral microbiota, thereby inhibiting the growth of pathogenic bacteria that cause inflammation around dental implants. The formula typically utilizes specific strains of lactic acid bacteria, such as *Lactobacillus plantarum* and *Lactobacillus brevis*, which exhibit high adherence to the oral mucosa and produce antimicrobial substances. It is intended to prevent the progression of peri-implant mucositis to peri-implantitis and maintain long-term implant stability.

Brand names: AB-Implalac

Beyond the preview

Go deeper on AB-Implalac.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AB-Implalac.

Explore the full profile